Leadership

Proven executives with successful exits, pharmaceutical commercialisation, and global market experience.

Viropin Team

  • Dr Anna Campbell

    Chair

    PhD in Biotechnology. Former Managing Director of AbacusBio, an international genetics company, she helped expand into 22 countries. Co-founder of Zestt Wellness and Viropin Pharmaceutical. Former Chair of Otago Innovation Ltd, former Director of Genomics Aotearoa and former Director of Acceligen, a US gene technology company. Extensive commercial experience across the UK, Australia, the Middle East, China, and India.

  • Darcy Schack

    Chief Executive Officer

    A disruptive innovator with a background in engineering and physics from Canada's oil industry. Co-founder of Zestt Wellness and Viropin Pharmaceutical, driven by a personal health journey and a commitment to solutions that materially improve patient outcomes.

  • Dr Paul Spence

    Chief Scientific Officer

    DPhil in Molecular Virology, University of Oxford. Experienced in commercialising scientific innovation from big pharma to VC-backed startups. Conceived, designed, and executed the production of a dual HIV antigen diagnostic kit, and led multi-million-dollar collaborations to develop new drug targets for CNS disorders. One of the original inventors of NAMZARIC®, a combination drug product for the treatment of Alzheimer's disease.

  • Andrew Cotterill

    Chief Operating Officer

    International operations and market development specialist. Previously led export development across the Middle East, Asia, and North America for one of the world's largest fresh produce companies. Co-founder of SCARAB Group, a UAE-based investment firm. Based in Germany, he leads Viropin's investor and partner relationships.

  • Dr Greg Cook

    Lead Microbiologist

    Deputy Vice-Chancellor (Research & Innovation), University of Otago. World-leading microbiologist specialising in bacterial physiology and antimicrobial resistance. Global expert in tuberculosis and bacterial energetics as a new target space for drug development.

  • Lisa Shi

    Director, China

    Specialist in international trade with extensive knowledge of China market regulations and access. Master of Arts, University of Auckland.

  • Danny Chan

    Director

    Investor and director with a track record of successful exits, including Academic Colleges Group (ACG), the private education group he co-founded, which was sold to Pacific Equity Partners. Holds multiple directorships across private and public New Zealand companies. BCA with Honours from Victoria University of Wellington.